Generic Prilosec Launch Awaits Negotiations Between Andrx And Schwarz
Executive Summary
Andrx is considering licensing its 180-day exclusivity for generic omeprazole to Schwarz Pharma following an Oct. 11 federal court ruling that Andrx' product infringes AstraZeneca's Prilosec patents, but Schwarz' does not
You may also be interested in...
Neurontin, Rebetol Generics Could Be Affected By “Shared Exclusivity” Ruling
A federal court decision invalidating FDA's "shared exclusivity" policy for first-to-file ANDAs poses another potential complication to the launch of generic versions of Pfizer's Neurontin (gabapentin)
Neurontin, Rebetol Generics Could Be Affected By “Shared Exclusivity” Ruling
A federal court decision invalidating FDA's "shared exclusivity" policy for first-to-file ANDAs poses another potential complication to the launch of generic versions of Pfizer's Neurontin (gabapentin)
Omeprazole Generic Will Stay: Schwarz Does Not Infringe Prilosec Patent
Schwarz' omeprazole does not infringe AstraZeneca's Prilosec patents because the generic does not contain an alkaline reacting compound, a D.C. federal appeals court affirmed Dec. 11